Description: Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
Home Page: www.sernova.com
The Stiller Centre
London,
ON
N6G 4X8
Canada
Phone:
519 858 5126
Officers
| Name | Title |
|---|---|
| Mr. James T. Parsons CPA-CA, MAcc | CFO & Director |
| Dr. Frank Shannon M.D. | Senior VP of Clinical Development and Regulatory Affairs |
| Dr. Modestus Obochi M.B.A., Ph.D. | Chief Business Officer |
| Mr. Jonathan M. N. Rigby M.B.A., MBA | Executive Chairman & CEO |
| Mr. Douglas Maret | Chief Science Officer |
| Mr. David Burke | Vice President of Investor Relations |
| Ms. Marylyn Rigby | Chief Communications Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 26.9759 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |